Patricia Piris

Patricia Piris

Auto-generated profile, based on publicly available information

Patricia Piris

Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm UMR1068, CNRS UMR7258, Aix-Marseille Université UM105, Institut Paoli Calmettes – Faculté de Pharmacie, Marseille, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in EBioMedicine
Verified
Journal Article
Open access
MRMaïlys Rossi
Maïlys Rossi
JTJulie Talbot
Julie Talbot
PPPatricia Piris
Patricia Piris
LMLe Grand Marion
Le Grand Marion
MMMarie-Pierre Montero
Marie-Pierre Montero
MCManon Carré
Manon Carré
Medulloblastoma is the most frequent brain malignancy of childhood. The current multimodal treatment comes at the expense of serious and often long-lasting side effects. Drug repurposing is a strategy to fast-track anti-cancer therapy with low toxicity. Here, we showed the ability of β-blockers to potentiate radiotherapy in medulloblastoma with bad prognosis. Medulloblastoma cell lines, patient-derived xenograft cells, 3D spheroids and an innovative cerebellar organotypic model were used to identify synergistic interactions between β-blockers and ionising radiations. Gene expression profiles of β-adrenergic receptors were analysed in medulloblastoma samples from 240 patients. Signaling pathways were explored by RT-qPCR, RNA interference, western blotting and RNA sequencing. Medulloblastoma cell bioenergetics were evaluated by measuring the oxygen consumption rate, the extracellular acidification rate and superoxide production. Low concentrations of β-blockers significantly potentiated clinically relevant radiation protocols. Although patient biopsies showed detectable expression of β-adrenergic receptors, the ability of the repurposed drugs to potentiate ionising radiations did not result from the inhibition of the canonical signaling pathway. We highlighted that the efficacy of the combinatorial treatment relied on a metabolic catastrophe that deprives medulloblastoma cells of their adaptive bioenergetics capacities. This led to an overproduction of superoxide radicals and ultimately to an increase in ionising radiations-mediated DNA damages. These data provide the evidence of the efficacy of β-blockers as potentiators of radiotherapy in medulloblastoma, which may help improve the treatment and quality of life of children with high-risk brain tumours. This study was funded by institutional grants and charities.

29 June 2023 in Chemical Science
Verified
Journal Article
Open access
PDF file
PPPatricia Piris
Patricia Piris
DBDuje Buric
Duje Buric
TYToshihide Yamasaki
Toshihide Yamasaki
PHPaul Huchedé
Paul Huchedé
MRMaïlys Rossi
Maïlys Rossi
MCManon Carré
Manon Carré
Brain tumors are an important cause of suffering and death. Glioblastoma are the most frequent primary tumors of the central nervous system in adults. They are associated with a very poor prognosis, since only 10% of GBM patients survive 5 years after diagnosis. Medulloblastoma are the most frequent brain malignancies in childhood; they affect the cerebellum in children under 10 years of age in 75% of cases. The current multimodal treatment comes at the expense of serious and often long-lasting side effects. Herein, we propose the synthesis of a library of novel alkoxyamines as anticancer drug candidates. The most efficient molecule, ALK4, was selected based on its ability to inhibit both survival and migration of GBM and MB cells in 2D cultures and in 3D tumor spheroids. A fluorescent derivative was used to show the early cytosolic accumulation of ALK4 in tumor cells. Spontaneous homolysis of ALK4 led to the release of alkyl radicals, which triggered the generation of reactive oxygen species, fragmentation of the mitochondrial network and ultimately apoptosis. To control its homolytic process, the selected alkoxyamine was bioconjugated to a peptide selectively recognized by matrix metalloproteases. This bioconjugate, named ALK4-MMPp, successfully inhibited survival, proliferation, and invasion of GBM and MB tumor micromasses. We further developed innovative brain and cerebellum organotypic models to monitor treatment response over time. It confirmed that ALK4-MMPp significantly impaired tumor progression, while no significant damage was observed on normal brain tissue. Lastly, we showed that ALK4-MMPp was well-tolerated in vivo by zebrafish embryos. This study provides a new strategy to control the activation of alkoxyamines, and revealed the bioconjugate ALK4-MMPp bioconjugate as a good anticancer drug candidate.

7 April 2026
Verified
Thesis
Closed access
PPPatricia Piris
Patricia Piris
Les glioblastomes, les tumeurs intracrâniennes les plus courantes chez l'adulte, sont des tumeurs agressives présentant des défis thérapeutiques uniques. Les Médulloblastomes (MB) sont, quant à eux, les tumeurs malignes intracrâniennes les plus courantes dans la population infantile. Les alcoxyamines (R1–ONR2R3) sont des molécules capables de s’homolyser, pour générer : 1) un radical alkyle hautement toxique (R1•), 2) un nitroxyde non toxique (R2R3NO•).Le présent projet vise à synthétiser de nouvelles alcoxyamines, et de contrôler leur homolyse par couplage à un peptide spécifiquement reconnu par les métalloprotéases matricielles (MMP), des enzymes surexprimées dans le microenvironnement tumoral.Plus de 100 nouvelles alcoxyamines ont été synthétisées et l’évaluation de leur activité cytotoxique sur modèles cellulaires 2D et sphéroïdes 3D de GBM et de MB ont conduit à la sélection d’une molécule, ALK4. Son mécanisme d’action a été déterminé : la libération des radicaux alkyles induit un stress oxydatif, des dommages mitochondriaux importants, déclenchant finalement l'apoptose des cellules.ALK4 a été couplé à un peptide ciblant les MMP pour générer un bioconjugué original ALK4-MMPp. La libération de l’alcoxyamine, est responsable de l’efficacité dose-dépendante des radicaux alkyles sur sphéroïdes tumoraux 3D de GBM et MB. La mise au point de modèles organotypiques innovants, replaçant les masses tumorales dans leur environnement d’origine, a permis de valider les bénéfices de ALK4-MMPp. Enfin, l’absence de toxicité du bioconjugué a été montrée sur modèles de Zebrafish, faisant d’ALK4-MMPp une molécule aux propriétés anticancéreuses particulièrement prometteuses.